These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

113 related articles for article (PubMed ID: 11153401)

  • 1. Drug review "surprises" reader.
    Shulman RW
    Can Fam Physician; 2000 Dec; 46():2381-3. PubMed ID: 11153401
    [No Abstract]   [Full Text] [Related]  

  • 2. Olanzapine for the treatment of tardive dyskinesia.
    Almeida OP
    J Clin Psychiatry; 1998 Jul; 59(7):380-1. PubMed ID: 9714267
    [No Abstract]   [Full Text] [Related]  

  • 3. Expected incidence of tardive dyskinesia associated with atypical antipsychotics.
    Glazer WM
    J Clin Psychiatry; 2000; 61 Suppl 4():21-6. PubMed ID: 10739327
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Neuroleptic malignant syndrome after addition of haloperidol to atypical antipsychotic.
    Mujica R; Weiden P
    Am J Psychiatry; 2001 Apr; 158(4):650-1. PubMed ID: 11282706
    [No Abstract]   [Full Text] [Related]  

  • 5. Blind, controlled, long-term study of the comparative incidence of treatment-emergent tardive dyskinesia with olanzapine or haloperidol.
    Tollefson GD; Beasley CM; Tamura RN; Tran PV; Potvin JH
    Am J Psychiatry; 1997 Sep; 154(9):1248-54. PubMed ID: 9286184
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Marked reduction of tardive dyskinesia with olanzapine.
    Littrell KH; Johnson CG; Littrell S; Peabody CD
    Arch Gen Psychiatry; 1998 Mar; 55(3):279-80. PubMed ID: 9510225
    [No Abstract]   [Full Text] [Related]  

  • 7. Hyperprolactinemia in response to antipsychotic drugs: characterization across comparative clinical trials.
    Kinon BJ; Gilmore JA; Liu H; Halbreich UM
    Psychoneuroendocrinology; 2003 Apr; 28 Suppl 2():69-82. PubMed ID: 12650682
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Safety of olanzapine.
    Beasley CM; Tollefson GD; Tran PV
    J Clin Psychiatry; 1997; 58 Suppl 10():13-7. PubMed ID: 9265911
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Olanzapine in the treatment of tardive dyskinesia: a report of 2 cases.
    Agarwal V; Kumar P
    J Clin Psychiatry; 2001 Apr; 62(4):298-9. PubMed ID: 11379849
    [No Abstract]   [Full Text] [Related]  

  • 10. Olanzapine versus placebo and haloperidol: acute phase results of the North American double-blind olanzapine trial.
    Beasley CM; Tollefson G; Tran P; Satterlee W; Sanger T; Hamilton S
    Neuropsychopharmacology; 1996 Feb; 14(2):111-23. PubMed ID: 8822534
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Tardive dyskinesia associated with olanzapine monotherapy.
    Ananth J; Kenan J
    J Clin Psychiatry; 1999 Dec; 60(12):870. PubMed ID: 10665640
    [No Abstract]   [Full Text] [Related]  

  • 12. Ondansetron for tardive dyskinesia.
    Zullino DF; Eap CB; Voirol P
    Am J Psychiatry; 2001 Apr; 158(4):657-8. PubMed ID: 11282718
    [No Abstract]   [Full Text] [Related]  

  • 13. Risperidone and tardive dyskinesia: a case of blepharospasm.
    Mullen A
    Aust N Z J Psychiatry; 2000 Oct; 34(5):879-80. PubMed ID: 11037386
    [No Abstract]   [Full Text] [Related]  

  • 14. Olanzapine for primary negative symptoms.
    Licht RW
    Am J Psychiatry; 1998 Aug; 155(8):1133-4. PubMed ID: 9699711
    [No Abstract]   [Full Text] [Related]  

  • 15. The effects of olanzapine, risperidone, and haloperidol on plasma prolactin levels in patients with schizophrenia.
    David SR; Taylor CC; Kinon BJ; Breier A
    Clin Ther; 2000 Sep; 22(9):1085-96. PubMed ID: 11048906
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Olanzapine versus haloperidol in the treatment of schizophrenia and schizoaffective and schizophreniform disorders: results of an international collaborative trial.
    Tollefson GD; Beasley CM; Tran PV; Street JS; Krueger JA; Tamura RN; Graffeo KA; Thieme ME
    Am J Psychiatry; 1997 Apr; 154(4):457-65. PubMed ID: 9090331
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The economic consequences of a drug-drug interaction.
    Shad MU; Marsh C; Preskorn SH
    J Clin Psychopharmacol; 2001 Feb; 21(1):119-20. PubMed ID: 11199940
    [No Abstract]   [Full Text] [Related]  

  • 18. Dosing the antipsychotic medication olanzapine.
    Nemeroff CB
    J Clin Psychiatry; 1997; 58 Suppl 10():45-9. PubMed ID: 9265916
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Olanzapine: efficacy in treating the positive and negative symptoms of schizophrenia.
    Gray R
    Ment Health Care; 1998 Feb; 1(6):193-4. PubMed ID: 9791411
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Olanzapine-induced tardive dystonia.
    Dunayevich E; Strakowski SM
    Am J Psychiatry; 1999 Oct; 156(10):1662. PubMed ID: 10518183
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 6.